Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cambridge Antibody Technology Group PLC

Division of AstraZeneca PLC

Latest From Cambridge Antibody Technology Group PLC

Immatics $58m Series E To Fund T-Cell Receptor-Based IO Therapies

The clinical-stage biopharma's latest financing of $58m will be used to progress its immunotherapy pipeline and proprietary platform, bringing its funding to date to just over $230m.

Financing Companies

Deal Making: If I Knew Then What I Know Today

David Chiswell, Jane Dancer and Konstantinos Efthymiopoulos shared lessons they have learnt over the years about deal making at this year's 'If I Knew Then What I Know Today' panel at the AngloNordic meeting in London.

Deals StartUps and SMEs

Appointments: Crescendo, Shield, Sarepta, Verona, Hansa, Astellas and Pluristem

This week’s roundup includes various high-level appointments by companies including Vencerx Therapeutics, which has elected a new CEO, Shield Therapeutics, Crescendo Biologics, Pluristem Therapeutics, Sarepta Therapeutics and Verona Pharma.

Appointments BioPharmaceutical

AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline

AstraZeneca’s Shaun Grady is an affable dealmaker whose talents – honed over three decades inside the group – are being put to the test as global business development head to help ensure Britain’s second-biggest drugmaker can successfully transform itself, its therapy focus and pipeline. He tells In Vivo about his role leading AZ’s transaction execution, due diligence and alliance and integration management, while overseeing its collaborative “externalization” program, licensing and partnering, M&A and divestments.

Business Strategies Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Hamish Cameron, CEO
    Patrick Round, SVP, Dev.
    Lizzie Dant, VP, Fin.
  • Contact Info
  • Cambridge Antibody Technology Group PLC
    Phone: (44) 1223 471 471
    Milstein Building, Granta Park
    Cambridge, CB21 6GH